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THE RECENT JOINT POSITION statement released by the American College of Sports Medicine and the American Diabetes Association stated that "it is now well established that participation in regular physical activity canѧprevent or delay Type 2 Diabetes (T2D), and positively affect lipids, blood pressure, cardiovascular events, mortality and quality of life" (2) . During exercise, energy demand increases dramatically in skeletal muscle; consequently, skeletal muscle was among the first tissues to be investigated with regard to responses to exercise (21) . However, the diversity of the effects listed above indicates that exercise is a systemic phenomenon with impact that is not limited to one tissue. Indeed, more recent research has shown that signaling events within a wide range of cell types are affected by exercise (52) .
The present study focuses on the effects of exercise on monocytes, which are important in several aspects of the pathophysiology of T2D, including cardiovascular complications such as atherosclerosis [with a link to T2D that is largely due to the proatherogenic nature of glycated proteins and lipids (48) ]. Monocytes have roles in control of blood-borne lipid homeostasis via their contribution to reverse cholesterol transport (9, 29) and in paracrine control of inflammatory signaling (4); also, adherence of monocytes to the endothelial wall and their migration into the subendothelial space and differentiation into macrophage foam cells are crucial to the development of atherosclerosis (48) . The contribution of monocyte-mediated reverse cholesterol transport to healthy lipid homeostasis is a major focus of the present study: after uptake by monocytes, lipoprotein components are processed and presented to apolipoprotein A-1 (ApoA1), thus forming HDL-cholesterol, which acts to reduce cardiovascular risk, as cholesterol bound to this lipoprotein is transported to the liver for safe disposal (5, 9, 29) . This may be of considerable clinical importance: selective activation of this pathway in peripheral cells such as monocytes has been recommended as a potential therapeutic target for atherosclerosis (5) .
The ligand-activated nuclear receptor peroxisome proliferator-activated receptor-␥ (PPAR␥) is a regulator of the expression of numerous PPAR␥ target genes [i.e., genes bearing PPAR response elements (PPREs), to which activated PPAR␥ can bind] involved in metabolism, cell differentiation, and inflammation (44, 51) . Thus, the actions of synthetic agonists for PPAR␥ [e.g., thiazolidinediones such as rosiglitazone (27) ] in regulating PPAR␥ target gene expression are responsible for beneficial effects in the context of T2D (10) . However, the transcriptional activity of PPAR␥ may also be affected by its phosphorylation status, and kinases such as MAPK/ERK, AMP-activated protein kinase, and others have been associated with ligand-independent changes in PPAR␥ activity (6) .
With specific regard to monocytes, PPAR␥ has been reported to regulate inflammatory responses and atherogenesis via this cell type (20, 39, 46) . Importantly, because of differentiation of monocytes into macrophages and their subsequent migration into a wide variety of tissues, activation of PPAR␥ within monocytes/macrophages has been shown to be crucial to many systemic thiazolidinedione antidiabetic actions throughout the body (18, 20, 40) . In particular, upregulation, within monocytes/macrophages, of PPAR␥-regulated genes involved in lipid uptake and clearance and reverse cholesterol transport has been shown to promote lipid clearance and transport to the liver within HDL-cholesterol (5, 9, 29) .
However, thiazolidinediones such as rosiglitazone have been linked to negative patient outcomes; specifically, the publication of meta-and teleoanalyses of clinical rosiglitazone studies (38, 47, 50) has raised safety concerns regarding the increased risk of myocardial infarction and death from cardiovascular causes in rosiglitazone-treated patients. Therefore, because of the immense clinical importance of T2D and its related conditions in Western society, alternative means of inducing beneficial PPAR␥-dependent genomic effects without also causing such deleterious effects are urgently required.
Exercise may provide such an alternative: we and others have demonstrated that participation in exercise programs can affect PPAR␥-mediated signaling events to bring about antiatherogenic benefits over and above improvements in cardiovascular performance (7, 56, 57) . For example, sedentary participants in a low-intensity exercise program (walking 10,000 steps 3 times per week for 8 wk) exhibited increased monocyte PPAR␥ DNA-binding activity and enhanced expression within monocytes of the PPAR␥ target genes CD36, PPAR␥ coactivator-1␣ (PGC-1␣), and liver X receptor-␣ (LXR␣) and, consequently, upregulation of the LXR␣ target genes ATP-binding cassette (ABC) subfamily A member 1 (ABCA1) and ABC subfamily G member 1 (7) . In these subjects, beneficial alterations were observed in serum lipid profiles (increased HDL-cholesterol and decreased total cholesterol, LDL-cholesterol, and triglycerides), with increased HDL-cholesterol correlating with PPAR␥ target gene expression, indicating that exercise had enhanced reverse cholesterol transport via PPAR␥-mediated effects within monocytes (7) . Similarly, participation in exercise also exerted anti-inflammatory effects due to upregulation of PGC-1␣ and priming of monocytes for differentiation into the alternative M2 macrophage phenotype (57) .
As the activity of PPAR␥ is primarily governed by the generation and/or availability of its ligands (44, 51) , it is possible that the above-mentioned effects were due to generation of PPAR␥ ligands during exercise. Therefore, we aimed to test the hypotheses that exercise is associated with generation of PPAR␥ ligands in the plasma and that this may activate PPAR␥ signaling within circulating monocytes, thus providing a mechanism to underpin the exercise-induced antiatherogenic benefits observed in previous studies (7, 56, 57) .
MATERIALS AND METHODS

Materials
Reagents were obtained from Sigma-Aldrich (Poole, UK) unless stated otherwise.
Participant Recruitment and Exercise Procedures
The present study comprised two phases: 1) an initial analysis of the response to an acute exercise bout (including a 24-h follow-up) and 2) an 8-wk training program comprising multiple exercise bouts (Table 1) .
Recruitment. In phase 1, a cohort of healthy active untrained individuals (n ϭ 9, 32 Ϯ 8 yr old, 179 Ϯ 11 cm height, 80 Ϯ 11 kg body mass) was recruited. In phase 2, a cohort of healthy active untrained individuals (n ϭ 8, 27.8 Ϯ 6.4 yr old, 175 Ϯ 7 cm height, 67 Ϯ 6 kg body mass) was recruited. In both cases, institutional ethical approval was granted; all participants signed confidential informed consent, health activity questionnaire, and blood collection forms prior to commencing their involvement.
Maximal testing. For phases 1 and 2, all participants completed an incremental cycling test to exhaustion on a Monark 824E cycle ergometer, with 30-W increases in power output every 3 min until volitional exhaustion. Heart rate (Polar s810, Polar Electro) and blood lactate and expired gases (Jaeger Oxycon Delta, Erich Jaeger, Hoechberg, Germany) were analyzed continuously throughout the test. All participants achieved at least two of the criteria for attainment of maximal O 2 consumption (V O2 max) (17) . Individual plots of power vs. submaximal O2 consumption were used to allow calculation of the power output corresponding to 70% V O2 max for each participant (176 Ϯ 56 and 161 Ϯ 41 W for phases 1 and 2, respectively) and, in the case of phase 2, to establish submaximal training intensities for the subsequent training regimen.
Training procedures and submaximal testing. In phase 1, a subsequent single 45-min bout of exercise at 70% V O2 max was performed. Blood and saliva samples were collected before and after exercise; additional samples were collected 1.5, 3, and 24 h after completion of the exercise bout. In phase 2, participants were assigned to an 8-wk training program comprising regular supervised training sessions, also with the same cycle ergometer and heart rate analysis ( Table 1 ). The program was designed to be progressive for training volume (17 . Venous blood and saliva samples were taken immediately before (Pre) and after (Post) this 45-min trial, and blood lactate, heart rate, and expired gases were analyzed as previously described. On completion of the training program, using the procedures described above, all participants repeated the maximal test.
Isolation of human peripheral mononuclear cells and plasma samples from whole blood. Blood samples from the antecubital vein were obtained via phlebotomy at the time points described above. Heparinized blood (10 ml) was diluted 1:1 in RPMI medium, layered over 10 ml of Histopaque-1077 Ficoll-Hypaque, and centrifuged at 400 g for 20 min.
Plasma samples were aspirated off as supernatants and stored at Ϫ80°C for subsequent analysis; an Instrumentation Laboratories IL-300 analyzer (Diamond Diagnostics, Holliston, MA) was used to determine triglyceride, total cholesterol, and HDL-cholesterol levels in the plasma samples. LDL-cholesterol was calculated using the Friedewald equation. All lipid analyses were carried out at the Diabetes Research Network Cymru laboratories (Swansea, UK).
Mononuclear cell fractions were carefully removed from the FicollHypaque interface and washed four times (500 g for 10 min) in 0.4 ml of phosphatase inhibitor solution (Active Motif, Rixensart, Belgium) and 7.6 ml of PBS. For validation purposes, direct-labeling monocyte purification experiments were carried out in some cases. Mononuclear cells were incubated with CD14-conjugated magnetic microbeads [Miltenyi Biotec, Surrey, UK; 1:5 (vol/vol) at 4°C for 15 min]. Excess microbeads were removed by centrifugation (300 g for 10 min) and removal of the resulting supernatant. Cells were passed through a 30-m-pore filter and added to a separator column (MACS LS, Miltenyi Biotec) attached to a magnetic separator unit (QUADROMACS). The column was washed to remove unbound cells and removed from the magnetic separator unit, and cells were forced through the column with a syringe plunger to elute labeled cells (i.e., CD14 ϩ monocytes). Measurements of plasma levels of reduced glutathione and salivary levels of IgA. Plasma reduced glutathione ([GSH]plasma) and salivary IgA (sIgA) levels were measured as described previously (32, 33) via commercially available ELISA using anti-GSH capture antibodies and horseradish peroxidase (HRP)-conjugated secondary antibodies for [GSH]plasma or anti-IgA capture antibodies and HRP-conjugated secondary antibodies for sIgA [Calbiochem Biosciences (Merck), Nottingham, UK]. Saliva samples were collected from a salivette containing a cotton pad placed under the tongue for 2 min, and the cotton pad was centrifuged (300 g for 2 min) to yield liquid saliva. As reported previously (32, 33) , all sIgA data were normalized for hydration status by normalization to salivary protein content [estimated using a Bio-Rad protein assay (Bio-Rad Laboratories, Basingstoke, UK)].
Use of plasma samples in PPRE-luciferase reporter assays. Human embryonic kidney (HEK-293) cells were maintained under standard conditions in DMEM (Invitrogen, Glasgow, UK) supplemented with 4 mM glutamine, 10% (vol/vol) FCS, and 100 IU of penicillinstreptomycin. Cells were transiently transfected in 96-well plates (seeded at a density of 2 ϫ 10 4 cells per well) with 100 ng each of PPRE-luciferase reporter construct, PPAR␥ expression vector, and Renilla reporter plasmid (pR6TK, Promega, Southampton, UK) using Lipofectamine (Invitrogen) according to the manufacturers' instructions. The PPAR␥ expression vector was made using a full-length copy of PPAR␥ cDNA cloned into pcDNA3 expression vector (Invitrogen). The plasmids-Lipofectamine cocktail in OptiMEM solution (Invitrogen) was incubated at room temperature for 30 min prior to addition to the cells. At 24 h after transfection, the medium was replaced with fresh DMEM, and cells were exposed to rosiglitazone (GlaxoSmithKline, Uxbridge, UK), 15-deoxy-⌬12,14-PGJ2 (15dPGJ2; Calbiochem, Darmstadt, Germany), and 13-hydroxy-9,11-octadecadienoic acid (13-HODE), which were solubilized in DMSO and used at working concentrations of 1, 3, and 5 M, respectively, while plasma samples (normalized for protein content) were added at 10% (vol/vol) to DMEM (instead of the addition of 10% FCS). Cells were harvested and lysed 24 h later, and luminescence was determined using a Dual Reporter Assay (Promega) according to the manufacturer's instructions. In each case, the ratio of luciferase to Renilla luminescence was used to normalize luminescence values to transfection efficiency. For investigation of the extent to which treatment with plasma samples was associated with phosphorylation of PPAR␥, phospho-specific Western blot experiments (see below) were carried out as previously described (8); PPAR␥ was detected in HEK-293 total-protein extracts as a doublet of ϳ55-kDa (nonphosphorylated PPAR␥) and ϳ60-kDa (phosphorylated PPAR␥) bands.
Isolation of RNA and RT-PCR assays. Total RNA was extracted using a RiboPure-Blood kit (Ambion, Huntingdon, UK) according to the manufacturer's instructions. Briefly, 5 ϫ 10 6 mononuclear cells or monocytes were washed in ice-cold PBS and lysed, and RNA was extracted using acid phenol-chloroform extraction, ethanol precipitation, and resuspension in RNase-free water. RNA was quantified and checked for purity using the ratio of its absorbance at 260 nm to its absorbance at 280 nm (only samples with a ratio Ͼ1.8 were deemed suitable for use). RNA samples were stored at Ϫ80°C before conversion to cDNA using the High-Capacity cDNA Archive Kit (Applied Biosystems, Warrington, UK) and then stored at Ϫ20°C. PPAR␥, CD36, LXR␣, ABCA1, PGC-1␣, cholesteryl ester transferase protein (CETP), lecithin-cholesteryl acyltransferase (L-CAT), and ApoA1 mRNA expression were analyzed using Fast SYBR Green Master Mix (Applied Biosystems) and compared with expression of GAPDH; primers with the following sequences were designed using Primer Express software (version 2.0, Applied Biosystems): 5=-GGAAGTGATGATGAACAGCAGC-3= and 5=-GAGACT-GTGTTGTCCTCAGCG-3= (CD36), 5=-CGCACTACATCTGCCA-CAGT-3= and 5=-TGAGGCGGATCTGTTCTTCT-3= (LXR␣), 5=-GCACTGAGGAAGATGCTGAAA-3= and 5=-AGTTCCTGGAA-GGTCTTGTTCA-3= (ABCA1), 5=-CGTGGCCGCAGATTTGAA-3= and 5=-CTTCCATTACGGAGAGATCCAC-3= (PPAR␥), 5=-TCAGTC-CTCACTGGGGGACA-3= and 5=-TGCTTCGTCAAAAACAG-3= (PGC-1␣), 5=-CGGCTCGGGCCACTTACACA-3= and 5=-GAGCAG-GCATGGGCATTGCC-3= (CETP), 5=-TGCTCTATTTCCTGCT-GCGCCAG-3= and 5=-ATGGGGATGCCCTGGTTGTCAC-3= (L-CAT), 5=-CCCCCTACAGCGACGAGCTG-3= and 5=-GGTGGCCT-TGGCGTGGTACT-3= (ApoA1), and 5=-TCCTGTGGCATCCA-CGAA-3= and 5=-GAAGCATTTGCGGTGGAC-3= (GAPDH). Thermocycling was carried out as follows: initial denaturation for 10 min at 95°C, followed by 40 cycles of 15 s at 95°C and 60 s at 60°C. Relative quantification of genes of interest was calculated using the 2 Ϫ⌬⌬CT formula, in which ⌬CT is the difference between the cycle threshold (CT) value for the gene of interest and C T value for the housekeeping gene. Data were included only if plots of log(RNA) vs. ⌬C T resulted in slopes between Ϫ0.1 and ϩ0.1, meaning that amplicon efficiencies were approximately equal, and if plots of log(template) vs. CT resulted in slopes of approximately Ϫ3.3 (for the housekeeping gene and the gene of interest; an ideal slope of Ϫ3.32 represents 100% PCR efficiency).
Western blot experiments. Western blot experiments were carried out as described elsewhere (32, 33) . Briefly, total protein extracts from mononuclear cells were prepared by treatment with 100 l of protein extraction/lysis buffer containing 1 mM protease inhibitor cocktail and 1 mg/ml phosphatase inhibitor (Active Motif), and protein content was estimated using a protein assay (Bio-Rad Laboratories). Samples were normalized for protein content (50 g of protein in each case) and subjected to SDS-PAGE, transferred to nitrocellulose, and probed with anti-CD36 or anti-PPAR␥ primary antibody (16 h, 1:1,000 dilution; Cell Signaling Technology, Danvers, MA) and then with HRP-labeled anti-rabbit IgG antibody (2 h, 1:2,000 dilution; Cell Signaling Technology). Proteins of interest were detected via enhanced chemiluminescence as 88-kDa (CD36) or 55-to 60-kDa (PPAR␥) immunogenic bands on Western blots. Band intensities were determined and quantitated using AC-1 BioImaging and VisionWorks LS Software systems (UltraViolet Products, Cambridge, UK).
Statistical Methods
Values are means Ϯ SE. Multiple comparisons were performed using one-way ANOVA, with post hoc analysis performed using Tukey's method; for nonmultiple comparisons, paired t-tests were used. Significance levels were set at P Ͻ 0.05.
RESULTS
On completion of the 8-wk training study, the participants showed significantly lower heart rate (175 Ϯ 14 and 156 Ϯ 15 beats/min at weeks 0 and 8, respectively, P ϭ 0.002; Fig. 1A ) and blood lactate (5.
sIgA significantly decreased to 53.2 Ϯ 12.7% of basal immediately postexercise at week 0 (P Ͻ 0.05); however, by week 4, the exercise-associated decrease in sIgA was nonsignificant (77.2 Ϯ 17.4% of basal, P ϭ 0.232), and by week 8, the sIgA postexercise response was further diminished (88.1 Ϯ 18.8% of basal, P ϭ 0.550; Fig. 1C) . Similarly, the same acute bout of exercise was associated with a significant decrease in
[GSH] plasma in untrained participants (week 0 Post ϭ 68.1 Ϯ 19.1% of week 0 Pre, P ϭ 0.004; Fig. 1D ). However, after 4 wk of training, this exercise-associated decrease in [GSH] plasma was blunted (week 4 Post ϭ 76.4 Ϯ 13.9% of week 4 Pre, P ϭ 0.016), and after 8 wk of training, there was no significant change in [GSH] plasma following an acute bout of exercise (week 8 Post ϭ 101.4 Ϯ 13.7% of week 8 Pre, P ϭ 0.846).
Thus, the data shown in Fig. 1 support the hypothesis that several systemic parameters, including physiological (heart rate), metabolic (lactate production), immunological (sIgA production), and biochemical (consumption of [GSH] plasma , which reduces blood-borne reactive oxygen species to harmless forms while being converted to oxidized glutathione), were involved in training adaptations to the 8-wk exercise program.
To determine whether exercise was associated with generation of blood-borne PPAR␥ ligands, PPRE-luciferase gene reporter assays were performed. As expected, treatment of HEK-293 cells with the synthetic PPAR␥ ligand rosiglitazone (1 M for 24 h) induced strong PPRE-luciferase activity in cells that had been transfected with a PPAR␥ expression vector rosiglitazone-treated non-PPAR␥-transfected cells, respectively, P Ͻ 0.05 vs. respective PPAR␥-transfected samples; Fig. 2A ), indicating that this cell type does not express endogenous PPAR␥. Treatment with the natural PPAR␥ ligands 15dPGJ 2 (14) and 13-HODE (37, 55) also induced increases in PPRE-luciferase activity (9.90 Ϯ 1.06 and 4.80 Ϯ 0.35 RLU for 15d-PGJ 2 and 13-HODE, respectively, P Ͻ 0.05 vs. control in both cases), albeit less strongly than rosiglitazone.
Treatment of PPAR␥-expressing HEK-293 cells with week 0 plasma samples [10% (vol/vol) for 24 h] showed increased PPAR␥/PPRE-luciferase activity; importantly, this increase was significantly greater when cells were treated with plasma collected following the initial exercise bout (week 0 Post ϭ 123.4 Ϯ 9.7% of week 0 Pre, P Ͻ 0.05; Fig. 2B ). In contrast, PPRE-luciferase activity was negligible in plasma-treated cells not transfected with the PPAR␥ expression vector (1.16 Ϯ 0.09 RLU, P Ͻ 0.05 vs. respective PPAR␥-transfected samples; Fig. 2A ). Thus, these data suggest that PPAR␥ ligands were generated in the plasma as a result of exercise. Interestingly, this effect was blunted in weeks 4 and 8 of the exercise program (week 4 Post ϭ 118.2 Ϯ 13.6% of week 4 Pre and week 8 Post ϭ 109.5 Ϯ 9.6% of week 8 Pre, P Ͼ 0.05 in both cases; Fig. 2B ).
Western blotting was used to assess PPAR␥ expression and phosphorylation (8) . While PPAR␥ could not be detected in non-PPAR␥-transfected control samples (data not shown), a doublet of ϳ55-kDa (nonphosphorylated PPAR␥) and ϳ60-kDa [phosphorylated PPAR␥ (pPPAR␥)] bands was detected in all other samples (Fig. 2C) . The relative intensities of these two bands indicate that PPAR␥ was in a predominantly nonphosphorylated state in all samples (pPPAR␥-to-total PPAR␥ ratio ϭ 0.201, 0.102 Ϯ 0.053, and 0.162 Ϯ 0.161 for control, Pre, and Post, respectively; Fig. 2D ). Importantly, treatment with Pre or Post exercise plasma samples did not induce significant differences in the pPPAR␥-to-total PPAR␥ ratio.
For participants in phase 1, samples were taken before (Pre) and immediately after (Post) exercise and also at 1.5, 3, and 24 h after exercise. As with week 0 of the 8-wk program (see above) and as shown in our previous studies (32, 33) , this bout of exercise was associated with significant decreases in sIgA and [GSH] plasma (data not shown, P Ͻ 0.05 in both cases). The extended 24-h follow-up period in this experiment revealed downstream signaling consequences of participation in exercise. Significant increases (1.5-to 2.5-fold) in expression of the monocyte PPAR␥-regulated genes CD36, LXR␣, and ABCA1 (P Ͻ 0.05 in all cases) were observed in samples taken within 3 h of exercise (Fig. 3) , with gene expression returning to basal levels within 24 h of exercise. Gene expression of PPAR␥ itself, and also of PGC-1␣ [which has been reported to be encoded by a PPRE-bearing PPAR␥ target gene (22) ], followed a similar trend, with nonsignificant increases at 1.5 and 3 h. In contrast, analysis of expression of reverse cholesterol transport genes, the expression of which is not reported to be increased by PPAR␥ (11, 15, 35) , showed that L-CAT (Fig.  3F ) and CETP (data not shown) did not significantly increase, while ApoA1 mRNA could not be detected (suggesting that this gene is not expressed by monocytes or, at least, that its expression levels are below the sensitivity of the assay systems used in the present study). The lack of response of these non-PPAR␥ target genes indicates that the effects in CD36, LXR␣, and ABCA1 (and possibly also PPAR␥ and PGC-1␣) were specifically induced by exercise-triggered PPAR␥ signaling, rather than as part of a generalized response to exercise.
Although the data shown in Fig. 3A are from mononuclear cells, optimization experiments using CD14
ϩ selection monocyte purification columns (Miltenyi Biotec) showed that mRNA expression for the genes of interest in the present study was enriched by two-to sixfold in purified monocytes compared with mononuclear cell samples (5.71 Ϯ 1.09, 2.65 Ϯ 0.16, 2.21 Ϯ 0.58, and 4.62 Ϯ 0.45 for PPAR␥, CD36, ABCA1, and PGC-1␣, respectively). Importantly, differential expression in monocytes was comparable or greater for each of these genes than the "classical" monocyte marker gene CD14 (2.77 Ϯ 0.47 fold), suggesting that they are predominantly expressed in monocytes, rather than in other types of mononuclear cells.
Western blotting was used to determine expression of PPAR␥ and its target gene CD36 at the protein level in mononuclear cells (week 0 Pre and week 8 Pre) in participants in phase 2. As shown in Fig. 4 , although PPAR␥ expression underwent only nonsignificant increases (1.50 Ϯ 0.71 at week 8 compared with week 0, P Ͼ 0.05), CD36 expression was Fig. 4, C and D) . Importantly, the week 8 samples were taken Ͼ48 h after the previous bout of exercise, suggesting that any increases in expression were not associated with a single exercise bout but, rather, constituted sustained increases that occurred as a consequence of regular participation in exercise (i.e., 8 wk of adherence to a program comprising regular, repeated exercise; Table 1 ).
Finally, blood lipids were determined for each participant: at baseline (week 0 Pre), total cholesterol was 4.31 Ϯ 0.20 mM, triglycerides were 1.53 Ϯ 0.19 mM, HDL-cholesterol was 1.33 Ϯ 0.09 mM, and LDL-cholesterol was 2.29 Ϯ 0.17 mM. Thus, all data fell within "healthy/low-risk" categories [American Heart Association reference ranges (3)] for each parameter. A single submaximal standardized exercise bout did not elicit significant changes in blood lipids; also, when comparisons were made between blood lipid levels over the duration of the exercise program, significant decreases in triglycerides (68.0 Ϯ 13.4%, P Ͻ 0.05) and borderline-significant decreases in total cholesterol (86.6 Ϯ 17.0%, P Ͻ 0.10), but no significant changes in LDL-or HDL-cholesterol, were seen.
DISCUSSION
We present data that support the widely held view that exercise is associated with beneficial effects, and we demonstrate several monocyte-associated exercise-induced PPAR␥ signaling events. The aim of the present study was to elucidate the PPAR␥ signaling events triggered by exercise and, particularly, by regular exercise training, for example, the downstream effects in terms of gene expression patterns within monocytes and their likely accompanying functional consequences with regard to antiatherogenic and/or anti-inflammatory effects.
It is well established that, in skeletal muscle, exercise upregulates PPAR␥-controlled genes to promote mitochondrial biogenesis, aerobic respiration, and other exercise-triggered benefits. For example, exercise leads to increases in PPAR␥ activity within skeletal muscle (42) , while comparable ϳ2.5-fold increases in PPAR␥ expression and, also, expression of the PPAR␥ coactivator PGC-1␣ were seen in two separate studies 3 h after a single bout of exercise (16, 30) . Moreover, a transcriptional map of the effects of exercise on skeletal muscle has recently been published, and many PGC-1␣/ PPAR␥-regulated genes (e.g., CD36) were among those upregulated (25) . However, if exercise is a systemic phenomenon, its effects will not be limited to a single tissue; therefore, we investigated whether parallel exercise-associated benefits may potentially occur in monocytes via exercise-induced upregulation of PPAR␥-controlled monocytic genes.
In contrast to skeletal muscle, exercise-related signaling events in monocytes have not been so intensively studied. To our knowledge, this study is novel, in that it demonstrates that exercise is associated with increased levels of PPAR␥ ligands in the plasma and that PPAR␥ signaling can be triggered by exercise to exert beneficial effects in circulating monocytes. In light of the data presented in Fig. 2 , we propose that generation of PPAR␥ ligands in the blood during exercise may lead to PPAR␥ activation in circulating monocytes and, hence, upregulation of PPAR␥ target genes (Figs. 3 and 4) . As mentioned above, it is possible that the upregulation of PPAR␥-regulated genes in the present study may be due to ligandindependent alteration of PPAR␥ transcriptional activity. Several studies have demonstrated that receptor-mediated events may lead to changes in PPAR␥'s phosphorylation status and, thence, to its activation or inactivation (6, 23) ; for example, exercise-associated alterations in blood-borne levels of insulin and/or in the ability of insulin to bring about its downstream effects (e.g., the impact of exercise-induced inflammation on insulin receptor substrate-1 tyrosine phosphorylation and, thus, the extent to which insulin receptor occupancy is transduced to downstream kinase activity) have been reported (reviewed in Ref. 26 ). Also, it is possible that exercise may be associated with a physical change that could impact PPAR␥; for example, the rate of blood flow has been reported to influence PPAR␥ activation via ERK isoforms in endothelial cells (1) , an effect that may be mirrored in circulating monocytes during exercise. Importantly, the above-mentioned effects could lead to monocyte PPAR␥ activation that is not dependent on generation of PPAR␥ ligands. However, phospho-specific Western blot experiments (8) suggest that treatment of PPAR␥-expressing HEK cells with plasma from exercising participants did not increase PPAR␥ phosphorylation and, also, that there was no difference between "preexercise" and "postexercise" samples with regard to PPAR␥ phosphorylation (Fig. 2, C and D) .
It should be stressed that HEK cells may not express all the signaling agents that might influence PPAR␥ phosphorylation; therefore, this experimental system may not accurately reflect the in vivo situation in all respects. Nevertheless, we conclude that while exercise-induced PPAR␥ activation may involve a ligand-independent component in vivo that we could not detect in our experimental system, the specific exercise-associated effects in Fig. 2 are likely to be due to the generation of ligands in the plasma of exercising individuals and subsequent liganddependent PPAR␥ activation within plasma-treated HEK cells. Several lipid-derived agents have been identified as PPAR␥ ligands [e.g., prostaglandins such as 15dPGJ 2 (14) and unsaturated fatty acids such as 13-HODE (37, 55) ], and as exercise is associated with changes in lipid metabolism (28) , it seems plausible that novel lipid metabolites could be generated within the blood of exercising participants [perhaps due to release of the products of cyclooxygenase and/or lipoxygenase-catalyzed reactions from circulating leukocytes (24)]. In this context, treatment with 15dPGJ 2 or 13-HODE induced significant increases in PPRE-luciferase activity in our reporter gene assay system ( Fig. 2A) . However, precise identification of the putative exercise-generated PPAR␥ ligands is beyond the scope of the present study.
Previous reports have linked upregulation of PPRE-bearing monocytic genes with a variety of beneficial functional effects. For example, LXR␣, a PPRE-bearing transcription factor analyzed in the present study, controls expression of a number of LXR␣ target genes that are involved in fatty acid metabolism and cholesterol homeostasis [e.g., ABCA1, which promotes the safe excretion of cholesterol and LDL by formation of Apo-I and HDL particles (9, 29) ]. Moreover, upregulation of the scavenger receptor CD36, another PPAR␥-regulated gene, leads to increased import of oxidized LDL; processing of oxidized LDL-derived cholesterol and its LXR␣-mediated export within HDL particles may provide an additional link between PPAR␥ activation and improvements in lipid profiles (7, 9) . Finally, the observation that PPAR␥ activation in monocytes is linked to priming for differentiation within tissues into the M2 macrophage phenotype and also to antiinflammatory paracrine effects (4, 57) suggests that activation of PPAR␥ within monocytes/macrophages may be linked to systemic anti-inflammatory actions (18) .
However, although parallel exercise-triggered effects may occur in muscle and monocytes, several differences exist between the respective pathways. Specifically, PPAR␥ exerts different effects through upregulation of a set of target genes in monocytes that is different from that in muscle (possibly due to differences in DNA packaging and/or availabilities of transcriptional coactivators in the respective tissues). However, PPAR␥ is involved in the systemic regulation and integration of lipid metabolism throughout the body (39) . Hence, PPAR␥ carries out complementary functions in diverse tissues; for example, exercise-triggered PPAR␥ signaling is involved in stimulation of adipocyte triglyceride hydrolysis, so as to boost release of fatty acids into the bloodstream (52) and also to increase expression of genes linked to oxidative metabolism of fats within skeletal muscle (30) . Thus, although different genes are activated in different tissues, a complementary array of effects is induced, and the systemic impact is broadly beneficial. Our study's identification of monocytes as an exerciseresponsive tissue, in which PPAR␥ can be activated to upregulate genes such as LXR␣, CD36, PGC-1␣, and ABCA1, is in line with this concept.
In the present study, upregulation of monocyte-expressed PPAR␥ target genes was seen at the mRNA level Ͻ3 h after a single bout of exercise (Fig. 3 ), but this effect persisted for Ͻ24 h. In contrast, after the 8-wk program, increases in PPAR␥ target gene expression were seen at the protein level in samples taken Ͼ48 h after the previous bout of exercise, suggesting that, in this case, the increase is not due to an acute response to an exercise bout. Thus, the following question is raised: can the effects of each individual exercise bout "coalesce," so that, after an extended program of regular frequent exercise, a more sustained effect is evident? Further experiments are needed to investigate this possibility more fully.
In the present study, these PPAR␥ signaling effects were associated with decreases in total cholesterol and triglycerides, but not with significant changes in HDL-or LDL-cholesterol. Because of the intensity of the exercise program to be undertaken, the participants recruited into the present study were fit, active individuals. It was not surprising that they exhibited healthy/low-risk values with regard to all four of the lipid parameters studied (3); however, one may speculate that, in cohorts of individuals with suboptimal blood lipid profiles, exercise-induced upregulation of monocytic lipid-handling genes would function to bring lipid levels to within the healthy/ low-risk range. In previous studies where participants did not exhibit healthy/low-risk values (3) for these parameters at baseline, larger statistically significant HDL-and LDL-cholesterol effects were seen (7, 56, 58) ; in our previous study, exercise-induced changes in HDL-cholesterol significantly correlated with Pre vs. Post changes in PPAR␥ target gene mRNA expression (7), while exercise (sometimes in combination with dietary interventions) has been shown to normalize blood lipid profiles in studies carried out on hypercholesterolemic populations (31). While we acknowledge that this issue and others, such as the nature and small size of the cohort (and the accompanying data variability), are limitations to the present study, ongoing studies within our research group are investigating the effects of exercise on larger cohorts and cohorts of at-risk individuals with suboptimal lipid profiles. In particular, we aim to establish whether the PPRE-luciferase system responds similarly when treated with plasma samples from T2D and non-T2D cohorts, given that similar exercise responses have been shown in T2D and non-T2D cohorts (albeit with regard to skeletal muscle, rather than monocytes) in previous exercise studies (16, 43) .
It is well established that regular training influences a range of inflammatory markers (12, 49, 53) in a manner sensitive to exercise intensity and duration (13, 54) . The standard response to any effective training program is that the same absolute intensity elicits a reduced physiological perturbation compared with the pretraining response. By presenting diminished postexercise increases in blood-borne PPAR␥ ligands over the course of the 8-wk program, alongside the expected blunting of postexercise heart rate, lactate, sIgA, and [GSH] plasma responses over the same period, the present work has provided an additional parameter by which a training program may reduce the relative stimulus of a given standardized acute exercise bout. These observations are entirely predictable, given the usual principles of training planning whereby ever-greater absolute intensities are needed to provide sufficient disruption of homeostasis to allow for continued training adaptations (36, 51) . However, they are, to our knowledge, novel in their application of this principle to exercise-induced PPAR␥ signaling. Importantly, given the widely acknowledged benefits of exercise-induced PPAR␥ signaling, they provide additional support to the concept of a need to tailor exercise programs to participants' fitness levels to elicit optimally beneficial effects in each case. Thus, while relatively intense exercise was required to activate PPAR␥ signaling in the cohort of fit, active individuals under investigation in the present study, we and others have reported that low/moderate-intensity exercise (i.e., training programs based on brisk walking) is sufficient to activate PPAR␥ in cohorts of sedentary individuals (7, 56 -58) .
It has been well established for several years that exercise is associated with a multitude of benefits, including the prevention and/or treatment of metabolic disorders such as T2D (2) . While the present study involved healthy participants and, thus, detected few overt improvements in lipid profiles, individuals with T2D exhibit decreased PPAR␥/PGC-1␣ (34, 41) and dyslipidemia (2) . Therefore, if individuals with T2D were to respond in a manner similar to the participants in the present study, and T2D and non-T2D cohorts have been shown to respond to a similar extent to exercise (16, 43) , it is possible that the exercise-associated effects seen here could help normalize PPAR␥ signaling and, thus, improve the blood lipid profiles of the individuals. Thus, the effects described here could potentially contribute to prevention of the development of metabolic disorders such as T2D in healthy or at-risk individuals or to normalization of aberrant metabolic function in individuals with disorders such as T2D.
In conclusion, the present study presents evidence that exercise-associated generation of PPAR␥ ligands activates PPAR␥ signaling events that result in upregulation of mono-cytic PPAR␥ target genes. This may constitute a novel beneficial effect of exercise in the context of prevention and/or treatment of metabolic disorders such as T2D and its complications.
